SCIENTIFIC PROGRAM ::
Welcome & Introduction
Silvano Focardi (Rector University of Siena)
David Rotella (President, ACS)
Roberto Pellicciari (President, EFMC)
Luisa Mosti (President, Division of Medicinal Chemistry ICS)
| Plenary Lectures (Chair - Giovanni Gaviraghi) | ||
| Julian Adams
(Infinity Pharmaceuticals Cambridge MA) |
Cancer Drug Discovery | |
| Carlo Melchiorre
(University of Bologna, Italy) |
Multi-target-directed drugs for neurodegeneration | |
| Coffee Break | ||
| Hit to Lead to Candidate | ||
| David Rees
(Astex Therapeutics) |
Fragment Based Drug Discovery: From Crystal to Clinic | |
| Daniele Donati (GSK Psychiatry CEDD Verona) |
Identification and optimisation of a novel series of selective 5HT2c antagonists | |
| Jeffrey Albert (AstraZeneca, Wilmington, US) |
Fragment-based lead generation and structure-based design for the discovery of high affinity beta-secretase inhibitors | |
| Poster Session 1 | ||
| Cancer (Chair - Peter Wipf, University of Pittsburgh) | |
| Antonello Mai (Universita' degli Studi Roma, Italy) |
Epigenetic small molecule modulators and cancer: an overview |
| David Newman (NCI, Frederick, MD) |
Mother Nature's Gifts to Cancer Chemotherapy |
Coffee Break | |
| William Gerwick (University of California, San Diego CA) |
Cancer Drug Discovery from Marine Cyanobacteria using Mechanism-Based and Mechanism-Blind Approaches |
| Christopher Straub (Novartis) |
Inhibitors of Apoptosis Proteins: Application of Structure Based Drug Design to the Taming of a Protein-Protein Interaction Target |
2 Short talks selected from Poster Presentations | |
| CNS (Chair - Graeme Robertson, Siena Biotech S.p.A.) | |||
| Giuseppe Ronsisvalle (University of Catania, Italy) |
Selective sigma ligands and their role in neurodegeneration | ||
| Albert Robichaud (Wyeth Research Princeton NJ) |
Design and SAR of potent, selective 5-HT6 Ligands and their potential utility as CNS disease therapeutics | ||
Coffee Break | |||
| Angelo Carotti (University of Bari, Italy) |
The MAO's long march: from toxic first-generation drugs to isoform-selective, reversible and multitarget inhibitors. | ||
| Arun Ghosh (Purdue University, West Lafayette, IN) |
Design of Potent and Selective Memapsin 2 (ß-Secretase) Inhibitors for Alzheimer's Disease | ||
2 Short talks selected from Poster Presentations | |||
| Poster Session 2 | |||
| Cancer (Chair - Roberto Pellicciari, EFMC President, University of Perugia) | ||
| Maurizio Botta (University of Siena, Italy) |
Small molecule kinases inhibitors: from virtual screening to in vitro and in vivo studies | |
| Pier Giovanni Baraldi (University of Ferrara, Italy) |
DNA minor groove binders (MGB) and tubulin inhibitors as antitumour agents | |
Coffee Break | ||
| Thomas Miller (Merck Research Laboratories, Boston) |
Histone Deacetylase Inhibitors | |
| Maurizio Pulici (Nerviano Medical Sciences, Italy) |
Aurora Kinase Inhibition: Identification and Expansion of Novel Scaffolds Leading to a Potent and Selective Compound with Favourable Antitumour Kinase Inhibition Profile | |
| 2 Short talks selected from Poster Presentations | ||
| CNS (David Rotella, Wyeth Pharmaceuticals) | ||
| Deen Tulshian (Schering Plough Research Institute, Kenilworth NJ) |
Discovery of Orally Active Nociceptin Receptor Agonists for the Management of Anxiety and Cough | |
| Chiara Ghiron (Siena Biotech S.p.A, Italy) |
The discovery of a novel series of alpha7 nAChR agonists | |
Coffee Break | ||
| Stefano Moro (University of Padova, Italy) |
Protein misfolding and neurodegeneration. | |
| James Monn ( Eli Lilly, Indianapolis) |
Discovery of mGlu2/3 Receptor Agonists for the Treatment of Psychiatric Disorders | |
Meeting Closure - Summary and Forward Looking
Roberto Pellicciari, EFMCDavid Rotella, ACS Medi
The conference will start on Sunday around 2:00 pm and will close on Tuesday late afternoon.
Poster Awards
Those submitting abstracts of exceptional quality and research impact may be asked to give a brief oral presentation during the regular sessions, in addition to presenting a poster. These researchers will also be considered for one of three Poster Prizes of approximately 1.000 euros each, one sponsored by Siena Biotech, one by the European Federation of Medicinal Chemistry, and the other by the American Chemical Society's Journal of Medicinal Chemistry.